Human tumor antigens recognized by T cells

Paul F. Robbins, Yutaka Kawakami

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltrating lymphocytes isolated from human melanomas. Investigations carried out in the past several years have resulted in the isolation of a number of the genes encoding antigens recognized by melanoma-reactive T cells. The ability of these products to serve as tumor regression antigens has now begun to be evaluated in clinical vaccine trials.

Original languageEnglish
Pages (from-to)628-636
Number of pages9
JournalCurrent Opinion in Immunology
Volume8
Issue number5
DOIs
Publication statusPublished - 1996 Oct
Externally publishedYes

Fingerprint

Neoplasm Antigens
T-Lymphocytes
Melanoma-Specific Antigens
Tumor-Infiltrating Lymphocytes
Adoptive Immunotherapy
Neoplasms
Melanoma
Vaccines
Clinical Trials
Genes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Human tumor antigens recognized by T cells. / Robbins, Paul F.; Kawakami, Yutaka.

In: Current Opinion in Immunology, Vol. 8, No. 5, 10.1996, p. 628-636.

Research output: Contribution to journalArticle

Robbins, Paul F. ; Kawakami, Yutaka. / Human tumor antigens recognized by T cells. In: Current Opinion in Immunology. 1996 ; Vol. 8, No. 5. pp. 628-636.
@article{de72460cec8242dbb82a619697eaa092,
title = "Human tumor antigens recognized by T cells",
abstract = "The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltrating lymphocytes isolated from human melanomas. Investigations carried out in the past several years have resulted in the isolation of a number of the genes encoding antigens recognized by melanoma-reactive T cells. The ability of these products to serve as tumor regression antigens has now begun to be evaluated in clinical vaccine trials.",
author = "Robbins, {Paul F.} and Yutaka Kawakami",
year = "1996",
month = "10",
doi = "10.1016/S0952-7915(96)80078-1",
language = "English",
volume = "8",
pages = "628--636",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Human tumor antigens recognized by T cells

AU - Robbins, Paul F.

AU - Kawakami, Yutaka

PY - 1996/10

Y1 - 1996/10

N2 - The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltrating lymphocytes isolated from human melanomas. Investigations carried out in the past several years have resulted in the isolation of a number of the genes encoding antigens recognized by melanoma-reactive T cells. The ability of these products to serve as tumor regression antigens has now begun to be evaluated in clinical vaccine trials.

AB - The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltrating lymphocytes isolated from human melanomas. Investigations carried out in the past several years have resulted in the isolation of a number of the genes encoding antigens recognized by melanoma-reactive T cells. The ability of these products to serve as tumor regression antigens has now begun to be evaluated in clinical vaccine trials.

UR - http://www.scopus.com/inward/record.url?scp=0030272856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030272856&partnerID=8YFLogxK

U2 - 10.1016/S0952-7915(96)80078-1

DO - 10.1016/S0952-7915(96)80078-1

M3 - Article

VL - 8

SP - 628

EP - 636

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 5

ER -